2012.4.19PCR标准化意义(福州).pptVIP

* References Branford S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;(17):2401-2409. Quintas-Cardama A, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113:6315-6321. Muller MC, et al. Molecular Response to First Line Imatinib Therapy is Predictive for Long Term Event Free Surival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV. Blood. 2008;112(11):129. Hughes TP, et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months correlates with long-term outcomes on imatinib (IM) at 72 months: An analysis from the international randomized study of interferon versus STI571 (IRIS) in patients with chronic phase chronic myeloid leukemia (CML-CP). Blood. 2008;112(11):129-130. Press RD, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCY in imatinib mesylate-treated patients with CML. Blood. 2006;107(11):4250-4256. Iacobucci I, et al. Achieving a major molecular response at the time of complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12:3037-3042. Cortes J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with Imatinib Mesylate. Clin Cancer Res. 2005;11:3425-3432. Paschka P, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694. Press RD, et al. A half-log increase in BCR-ABL